New osteoarthritis drug APPA-1 passes first safety check in small study
NCT ID NCT07429565
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new drug called APPA-1 in 40 healthy volunteers and people with osteoarthritis. The main goal was to see if the drug is safe and how the body processes it. Researchers also looked at how food and gender affect the drug. This is a first step to see if APPA-1 could help ease osteoarthritis symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Liverpool University Hospitals NHS Foundation Trust
Liverpool, Merseyside, L7 8XP, United Kingdom
-
University of Liverpool
Liverpool, L69 7ZB, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Bowlegs and knee surgery: does preoperative alignment change pain outcomes?
- Custom knee surgery tools aim for better fit and faster recovery
- Hands-On relief: which therapy eases knee arthritis pain best?
- Could a triple therapy tackle diabetes, high blood pressure, and arthritis at once?
- Can simple leg dangles or electrical pulses ease knee arthritis pain?
- CT scans track hip implant movement to predict Long-Term stability